Work

A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps7071

Authors: Martin S. Tallman, Jay Marshall Feingold, Alexander I. Spira, David Rizzieri, Ehab L. Atallah, Wendy Stock, Nitin Jain, Roland B. Walter, Ki Y. Chung

Institutions: Memorial Sloan Kettering Cancer Center, Virginia Cancer Specialists, Duke Medical Center, Medical College of Wisconsin, University of Chicago, The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Prisma Health

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889961083

Cites:

Cited by: 2

Related to: 10